✦ LIBER ✦

Long-term administration of active immunotherapy CAD106 in phase IIa open-label extension studies in Alzheimer's disease patients

✍ Scribed by Ana Graf; Niels Andreasen; Martin Farlow; Marie-Emmanuelle Riviere; Peter Quarg; Angelika Caputo; Igor Vostiar; Bengt Winblad; Jean-Marc Orgogozo

Book ID: 118468440
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 146 KB
Volume: 8
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2012.05.493

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.5.a.006 Long-term safety and tolerabil

P.5.a.006 Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease

✍ S. Bakchine; M. Rainer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Long-term safety and tolerability of pre

Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia

✍ K. Murphy; B. Zeiher; B. Herman; G. Atkinson; L. Pauer; L. Whelan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Safety, tolerability, and antibody respo

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

✍ Bengt Winblad; Niels Andreasen; Lennart Minthon; Annette Floesser; Georges Imber 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 606 KB

Long-term safety and tolerability of rot

Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: A prospective, open-label extension study

✍ Lawrence W. Elmer; Erwin Surmann; Babak Boroojerdi; Joseph Jankovic 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 408 KB

Long-term efficacy and safety of donepez

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

✍ S.L Rogers; L.T Friedhoff 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 303 KB

22 24-months on treatment: Open-label ph

22 24-months on treatment: Open-label phase I/II long-term study of enzyme replacement therapy (ERT) with Gene-Activated® human glucocerebrosidase (GA-GCB) in patients with type I Gaucher disease

✍ Ari Zimran; G. Altarescu; C. Fratazzi; R. Mensah; D. Elstein 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB